What we do Zim Laboratories Ltd develops and manufactures pharmaceutical formulations and pre-formulation ingredients, marketing products domestically and internationally, including innovative drug delivery platforms. |
Founded in 1,984 |
Market share Not a market leader but has strong presence in regulated and emerging markets with growing innovative product portfolio. |
Problem solved Provides affordable, effective formulations and innovative drug delivery solutions addressing specialty and generic pharmaceutical needs across multiple regions. |
Top clients or who we serve Serves global pharmaceutical markets including India, Europe, Australia, and emerging Pharmerging markets; B2B pharma clients and distributors. |
Key management - |
Our journey and innovations Incorporated in 1984; acquired ZIM Health Technologies (2019); launched patented Thinoral oral thin film platform; expanding presence via subsidiaries in Latvia, UAE, Australia. |
Where we operate India, Europe (EU/UK), Australia, Middle East including UAE, Pharmerging markets, and Rest of World territories. |
Top products or what we offer Pharmaceutical formulations, New Innovative Products (NIP), Oral Thin Films (OTF), nutraceuticals, and contract manufacturing services. |
Top brands Thinoral® (patented oral thin film), Sildenafil citrate OTF - first commercial European order; diversified pharma and nutraceutical portfolios. |
Raw materials needed Pharmaceutical raw materials and active pharmaceutical ingredients relevant to oral solid dose and oral thin film formulations. |
Raw materials supplier Global pharmaceutical raw material suppliers; details not specifically disclosed. |
Recurring vs cyclical contribution Predominantly recurring revenues from formulation sales and contract manufacturing; cyclical influences from regulatory approvals and market expansions. |
Our industry position Growing speciality pharma player with expanding innovative product pipeline targeting regulated and emerging markets. |
Financial highlights FY25 consolidated revenue Rs 3,790 crore, net profit Rs 121 crore; steady financials with investments in R&D and regulatory filings. |
Geographical revenue split Exports contribute about 85-88% of revenues; India accounts for around 10-13%, with growing presence in Europe, Middle East, and Pharmerging markets. |
Order book - |
Whats driving growth Focused R&D pipeline, innovative drug delivery technologies, regulatory approvals, international market expansion, and strategic partnerships. |
Our future plans Expansion of EU/UK facilities, launch of new Star Products in nutraceuticals and pharma, CAPA remediation for EU audits, and strategic equity fund raise. |
Our green promise Active energy conservation initiatives and efforts toward renewable energy adoption; focus on carbon emission reduction and sustainability practices. |
Our people and values Employs over 90 R&D scientists; promotes innovation culture and diversity; committed to anti-sexual harassment and employee welfare policies. |
Key challenges ahead Regulatory compliance especially CAPA remediation, competition from multinationals and generics, currency volatility, and maintaining growth momentum in niche markets. |
Interesting facts First commercial order for patented oral thin film in Europe; expanding scientific offices in UAE and subsidiaries worldwide; strong R&D centre recognition. |
Risks and strategy Risk management includes CAPA remediation, strategic partnerships, diversification, and market-specific regulatory compliance. |
